PLA2G7

Across TCGA pan-cancer cohorts, PLA2G7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLA2G7 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLA2G7 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PLA2G7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUSC, and BRCA are the cancer types where PLA2G7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.432	.006	28	view →
LUSC	OS	Median	All	0.190	0.678	<.001	24	view →
BRCA	OS	Median	All	0.125	0.578	.008	16	view →
BLCA	OS	Median	IV	0.089	0.599	<.001	12	view →
SKCM	OS	Median	III,IV	0.232	0.705	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLA2G7–UCEC (DFS)

Open the UCEC breakdown →